PDCD1 and neoplasm: A study by Rousseau et al. discovered that POLE mutations can serve as predictive biomarkers for patients with CRC or endometrial carcinoma treated with PD-1 antibodies, as these mutations are associated with increased TMB and tumor-infiltrating lymphocytes [107].